Karan Maxwell News Today

Kara N. Maxwell, MD, PhD, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer.

Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.

Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.

Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). Now, a recent study demonstrates men who have mutations in this gene have a high risk of developing aggressive prostate cancer. Their findings suggest men undergoing cancer-risk genetic testing should be checked for mutations in this gene as well.

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found.

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United

Men who inherit mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found.